Skip to main content
IONS
NASDAQ Life Sciences

Ionis Q3: Revenue $242.7M, Net Loss $110.0M; TRYNGOLZA Guidance Cut and Pelacarsen Royalty Write-Down

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$31.5
Mkt Cap
$6.551B
52W Low
$38.305
52W High
$86.74
52W Position info
18% below low
Off High info
64% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

IONS is trading near its 52-week low of $38.305 (18% below the low).

Summary

Ionis posted Q3 revenue of $242.7M and a $110.0M net loss, with DAWNZERA offsetting a sharp TRYNGOLZA decline; the 10-Q also details a pelacarsen-driven royalty liability re-estimate and two Roche collaboration terminations.


Key Events · Earnings and Guidance · IONS

  • Q3 Revenue Up 55%, Loss Narrows Sequentially

    Total revenue was $242.7M versus $156.7M a year earlier; net loss was $110.0M, or $0.66 per share, versus $128.6M a year earlier.

  • TRYNGOLZA Sales Collapse, DAWNZERA Carries Quarter

    TRYNGOLZA net sales fell to $9.3M from $31.8M a year earlier, while DAWNZERA rose to $36.8M from $0.7M and new ZANVASTRO contributed $2.2M.

  • Pelacarsen Failure Resets Royalty Liability

    After the Phase 3 miss, Ionis set expected pelacarsen royalties to zero and raised the SPINRAZA royalty cap payable to Royalty Pharma from $475M to $550M, moving the arrangement into contra-interest expense.

  • Roche Terminates Two Collaborations

    Roche terminated the Alzheimer's/Huntington's RNA program collaboration effective November 2026 and the separate Huntington's collaboration effective October 2026.


Analysis · IONS · Life Sciences

Revenue grew 55% to $242.7M in Q3, but the quality of that growth is mixed: DAWNZERA carried the quarter at $36.8M while TRYNGOLZA sales collapsed to $9.3M from $31.8M a year earlier, consistent with the guidance cut already flagged in this morning's 8-K. The 10-Q adds two items the headline release did not fully spell out. First, the pelacarsen Phase 3 failure forced Ionis to zero out expected pelacarsen royalties and raise the SPINRAZA royalty cap payable to Royalty Pharma from $475M to $550M, which flips the royalty financing into contra-interest expense going forward. Second, Roche terminated two collaborations (Alzheimer's/Huntington's programs), removing partnered pipeline optionality. With $1.9B of cash and investments and a $317.1M nine-month net loss, funding is not an immediate issue, but the widening loss and rising SG&A ($154.2M vs $96.8M) show the launch build-out is expensive while the newest launch underperforms.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IONS was trading at $31.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $38.31 to $86.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $32.32 info
Change: -$4.68 (-13%) info
Market Cap: $6.551B info
IONS
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $32.32 info
Change: -$4.68 (-13%) info
Market Cap: $6.551B info
IONS
Oct 23, 2026, 1:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.93
Real-time Price: $32.32 info
Change: -$10.61 (-25%) info
Market Cap: $6.551B info
IONS
Oct 20, 2026, 9:20 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $45.20
Real-time Price: $32.32 info
Change: -$12.88 (-28%) info
Market Cap: $6.551B info
IONS
Oct 16, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.56
Real-time Price: $32.32 info
Change: -$11.24 (-26%) info
Market Cap: $6.551B info